Bellerophon Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Stock-based compensation
Change in fair value of common stock warrant liability
Warrant amendment charge
Accretion and amortization of discounts and premiums on marketable securities, net
Issuance costs attributable to common stock warrant liability
Financing expense

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other non-current assets
Accounts payable, accrued research and development, accrued expenses and other liabilities

Net cash used in operating activities
Capital expenditures
Purchase of marketable securities
Proceeds from sale of marketable securities
Cash flows from financing activities:
Proceeds received from exercise of warrants
Proceeds received from exercise of options
Proceeds from exercise of warrants pending issuance of common shares
Proceeds from sale of Units in Secondary Offering, net of commissions and offering expenses
Proceeds from sale of Units in PIPE Offering, net of offering expenses
Proceeds from sale of Units in Direct Offering, net of commissions and offering expenses
Tax withholding payments for stock compensation
Net cash (used in) provided by financing activities

Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Change in unrealized holding gains on marketable securities, net
Conversion of warrant liability to common stock upon exercise of warrants
Unpaid expenses related to offerings
Reclassification of warrant liability to equity on amendment of warrant agreements
New right of use asset and operating lease

Comments